...
首页> 外文期刊>Cell adhesion & migration >Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy
【24h】

Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy

机译:Tenascin-C在心血管重塑中的作用:对诊断,预后评估和靶向治疗的潜在影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Fetal variants of tenascin-C are not expressed in healthy adult myocardium. But, there is a relevant re-occurrence during pathologic cardiac tissue and vascular remodeling. Thus, these molecules, in particular B and C domain containing tenascin-C, might qualify as promising novel biomarkers for diagnosis and prognosis estimation. Since a stable extracellular deposition of fetal tenascin-C variants is present in diseased cardiac tissue, the molecules are excellent target structures for antibody-based delivery of diagnostic (e.g., radionuclides) or therapeutic (bioactive payloads) agents directly to the site of disease. Against the background that fetal tenascin-C variants are functionally involved in cardiovascular tissue remodeling, therapeutic functional blocking strategies could be experimentally tested in the future.
机译:腱生蛋白C的胎儿变异体在健康的成年心肌中不表达。但是,在病理性心脏组织和血管重塑期间会发生相关的复发。因此,这些分子,特别是含有腱生蛋白-C的B和C结构域,可以被认为是用于诊断和预后评估的有希望的新型生物标记。由于在患病的心脏组织中存在胎儿肌腱蛋白-C变体的稳定的细胞外沉积,因此该分子是用于将抗体(例如放射性核素)或治疗剂(生物活性有效载荷)直接递送到疾病部位的基于抗体的出色靶结构。在胎儿腱糖蛋白-C变体功能性参与心血管组织重塑的背景下,治疗功能性阻断策略可在未来进行实验性测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号